Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hepatitis C virus experimental model systems and antiviral drug research.

Literature DB >> 20960298

Hepatitis C virus experimental model systems and antiviral drug research.

Abstract

An estimated 130 million people worldwide are chronically infected with hepatitis C virus (HCV) making it a leading cause of liver disease worldwide. Because the currently available therapy of pegylated interferon-alpha and ribavirin is only effective in a subset of patients, the development of new HCV antivirals is a healthcare imperative. This review discusses the experimental models available for HCV antiviral drug research, recent advances in HCV antiviral drug development, as well as active research being pursued to facilitate development of new HCV-specific therapeutics.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：
Antiviral Agents

Year: 2010 PMID： 20960298 PMCID： PMC2963037 DOI： 10.1007/s12250-010-3134-0

Source DB: PubMed Journal: Virol Sin ISSN： 1995-820X Impact factor: 4.327

190 in total

1. Transmission of hepatitis C virus infection to tree shrews.

Authors: Z C Xie; J I Riezu-Boj; J J Lasarte; J Guillen; J H Su; M P Civeira; J Prieto
Journal: Virology Date: 1998-05-10 Impact factor: 3.616

Review 2. Inhibition of HCV p7 as a therapeutic target.

Authors: Stephen Griffin
Journal: Curr Opin Investig Drugs Date: 2010-02

3. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus.

Authors: Hervé Lerat; Masao Honda; Michael R Beard; Kim Loesch; Jiaren Sun; Yan Yang; Michiari Okuda; Rainer Gosert; Shu-Yuan Xiao; Steven A Weinman; Stanley M Lemon
Journal: Gastroenterology Date: 2002-02 Impact factor: 22.682

4. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.

Authors: George Koutsoudakis; Eva Herrmann; Stephanie Kallis; Ralf Bartenschlager; Thomas Pietschmann
Journal: J Virol Date: 2006-11-01 Impact factor: 5.103

Hepatitis C virus experimental model systems and antiviral drug research.

1. Transmission of hepatitis C virus infection to tree shrews.

Review 2. Inhibition of HCV p7 as a therapeutic target.

3. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus.

4. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.

5. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

6. Non-A, non-B hepatitis in chimpanzees and marmosets.

7. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells.

8. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin.

9. Experimental infection of Tamarins with human non-A, non-B hepatitis virus.

10. Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection.

1. Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C.

Review 2. Passive immune neutralization strategies for prevention and control of influenza A infections.

3. Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay.

4. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.

5. Permissiveness of human hepatoma cell lines for HCV infection.